Study of Immune Responses and T Cell Targets in Adults with Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Myelofibrosis

What this Trial Is About

Researchers are studying how the immune system responds to myeloproliferative neoplasms MPN in adults who have or are suspected to have MPN. This observational study aims to identify specific immune cells, called T cells, that can recognize MPN cells and to find targets on these cancer cells that may be useful for future immune-based treatments. The study focuses on adults with conditions like polycythemia vera, essential thrombocythemia, primary myelofibrosis, post-PMF, or unclassifiable MPN, and also includes healthy donors for comparison. Participants will provide blood and bone marrow samples, which researchers will analyze using laboratory methods including genetic sequencing, cell analysis, and cell culture experiments. These tests will help identify T cell receptors and tumor antigens linked to MPN cells. The study will continue for about 10 years to thoroughly monitor and identify these immune responses. During the study, participants will contribute samples that enable detailed research on immune cells and genetic material related to MPN. Researchers will measure the presence of MPN-specific CD8 T cell clonotypes and their corresponding tumor antigens throughout the study period. Participants will not receive direct medical benefits, but their involvement will support the development of future immune-based therapies. The study will last approximately 10 years, allowing long-term observation and analysis.

Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm